Werfen Achieves FDA Clearance for ROTEM Sigma Cartridge
In a significant development for trauma care, Werfen announced that it has secured FDA 510(k) clearance for its ROTEM sigma complete cartridge. This advancement moves the application of ROTEM's viscoelastic testing system into the field of trauma management, addressing peri-operative hemorrhage and thrombosis assessments in a crucial timeframe.
Background on ROTEM Sigma
The ROTEM sigma system is a fully automated viscoelastic testing tool that offers real-time insights into a patient's coagulation dynamics. Traditionally utilized in cardiovascular surgery and liver transplantation, this clearance allows for extending its capabilities to trauma cases where quick intervention is vital. According to recent data, traumatic injuries account for approximately 10% of global deaths, with uncontrolled bleeding being a leading preventable cause.
The advancement of ROTEM sigma is particularly important given the challenging nature of trauma-induced coagulopathy, where rapid actionable information can impact patient outcomes significantly. Bill Crandell, Vice President for Commercial Operations at Werfen, emphasized that trauma teams often operate under extreme time pressure making swift treatment decisions critical. The introduction of ROTEM sigma in these settings enhances access to vital coagulation information needed to inform treatment decisions during trauma scenarios.
The Role of Viscoelastic Testing in Trauma
Current trauma management guidelines advocate for viscoelastic testing as a crucial part of a goal-directed approach to managing bleeding and coagulation issues. The ROTEM sigma facilitates personalized treatment strategies by assessing clot initiation, firmness, and stability at the point of care. This functionality allows healthcare providers to navigate complex clinical situations with greater confidence.
User-Friendly Features
One of the standout features of the ROTEM sigma system is its automated, cartridge-based system that minimizes manual steps, thereby reducing operator variability. Its intuitive touchscreen interface not only simplifies the testing process but also encompasses functions such as quality control and continuous monitoring. These innovative attributes make ROTEM sigma adaptable across various acute care environments, enhancing overall clinical workflow.
Indications for Use
The ROTEM sigma Thromboelastometry System is specifically designed for adult patients who require a semi-quantitative evaluation of their blood coagulation properties at both point-of-care and laboratory settings, although it is not intended for pre-hospital use. The system includes the following diagnostic assays:
- - INTEM C: Evaluates coagulation via the intrinsic pathway.
- - EXTEM C: Assesses coagulation via the extrinsic pathway.
- - FIBTEM C: Tests coagulation after blocking the contribution of platelets to clot firmness.
- - HEPTEM C: Assesses coagulation after inactivating heparin.
- - APTEM C: Evaluates coagulation while blocking fibrinolysis.
Conclusion
The FDA clearance of the ROTEM sigma cartridge represents a pivotal step in improving trauma care, enabling healthcare providers to make informed decisions based on timely coagulation assessments. As trauma care continues to evolve, Werfen's commitment to innovation positions it at the forefront of advancing medical technology aimed at enhancing patient outcomes. With the ROTEM sigma system, clinicians can access essential resources to provide effective care in life-threatening situations.
In an era where every second matters, the integration of advanced diagnostic solutions like the ROTEM sigma is crucial in transforming trauma management, ultimately leading to better survival rates and improved healthcare experiences.